Target: NPR-B

Indicant: Achondrogenesis

MOA & Molecule Type: Peptide CNP

Development stage: R&D

Summary: Achondrogenesis is a disease that causes problems in bone growth of cartilage and is caused by mutations in the FGFR3 gene and failure to produce proper bones.

In order to prevent the proliferation and differentiation of cartilage cells from being inhibited, CNP (C-type natural peptide) must activate NPR-B in cartilage to suppress the activity of RFP, an intermediate product in the FGFR3 signaling process.

Currently, the product approved as a treatment is Voxzogo one substance and has been approved as a "rare drug." Our company compared to existing treatments, the company has increased stability in the body by using D-amino acid and is developing treatments that are cartilage-specific and strong binding to NPR-B through material advancement.